СБОРНИК ТЕЗИСОВ
5
EVALUATION OF THE USE OF HEPATOPROTECTORS IN PATIENTS WITH CHRONIC
VIRAL HEPATITIS B
Yakubova N.S.
Samarkand State Medical University, Samarkand, Uzbekistan
Scientific adviser: Yarmuxamedova M.K.
The purpose of the study: To evaluate the effect of Phosphogliv on viral load and clinical and laboratory
parameters in patients with chronic hepatitis B.
Materials and research methods: We have analyzed 107 patients with CHB who applied on an outpatient
basis in 2019-2021 to the Hepatological Center of the Samarkand Regional Clinical Infectious Diseases
Hospital. All patient studied complaints, anamnesis, objective data. From laboratory studies, a complete
blood count was performed, liver tests by ELISA determined the antigens and antibodies of viruses B ,
C, D. To clarify the viral load before treatment and after 6 months, quantitative PCR was performed for
DNK - HBV . The observation group included patients with chronic hepatitis B without a delta agent, in
most of them ALT values were increased by 1.5 times, and the viral load was from 150 to 10
л
3, and also
without severe inflammation of the liver (F 0 ; F 0-F 1 F 1-F 2). To determine the degree of fibrosis, a
non-invasive method for examining the liver and - elastometry on the device " Fibroscan ".
Results and discussion: Phosphogliv , belongs to the group of essential phospholipids, is a combination
drug. It is known that phosphogliv contains phosphaditylcholine and trisodium salt of glycyrrhizic acid
and has immunomodulatory and antiviral effects. All patients received the drug enterally , 2 capsules 3
times a day, for 3 to 6 months.
Of the 107 patients examined, the age range was from 21 to 56 years. Among them, men 57% and women
53%. The main contingent were patients from the districts of the Samarkand region (83%). When
studying complaints, the patients mainly had weakness and fatigue ( 92%), they noted the severity and
periodic pain in the right hypochondrium (32.6%). On examination: no yellowness was detected on the
skin and visible mucous membranes, only 21% had subicteric sclera, no special deviations were noted
from the respiratory and circulatory organs. In 45.1% of patients, the liver protruded up to 2.0 cm from
the hypochondrium, in all the spleen was not palpable. The stool is colored, the urine is light. From the
anamnesis: 43% of CHB patients are ill before 5 years, 41% are ill before 10 years , the remaining 16%
do not know since when they have been ill. Of the epidemiological data, 72% of patients underwent
parenteral interventions, with dental services in 51%, blood transfusion in 7%, operations in 13% ( hernia
repair , appendectomy , caesarean section, hysterectomy , cholecystectomy ), frequent intravenous or
intramuscular injections - in 10%, in 19% of cases it was not possible to find out the cause, and HBsAg
was found in them by chance during examination during pregnancy. When applying, the parameters of
the general blood test were determined: anemia of the 1st degree in 47%, anemia of the 2nd degree was
detected in 51%, and the rest had a hemoglobin level within the normal range. Liver tests: the level of
bilirubin in all patients was normal, AST and ALT were increased by 74.7% from No. to 1.5 times the
norm, and in 25.3% of patients the enzymes were within the normal range. Enzyme immunoassay in all
patients revealed the presence of HBsAg tests and subsequently, by PCR, HBV DNA was determined
quantitatively and qualitatively. All were negative for HCV , HDV . Quantification by PCR was as
follows: 0.1±0.2 in 66% of patients; 0.2±0.3 in 44% of patients . Fibroscanning parameters corresponded
to clinical and laboratory data.
The level from 2.0 to 5.8 kPa was found in 77%, and in the rest from 5.9 to 9.2 kPa.
F 0-36% of the patient , F 0-F 1 in 55.6%, F 1-F 2 was observed in 8.4%.
Conclusions: The use of Phosphogliv in patients with chronic viral hepatitis B without a delta agent
contributes to the normalization of ALT , AST and a decrease in viral load.
References:
1.
Atamukhamedova, D., and N. Djalalova. "EPIDEMIOLOGICAL CHARACTERISTICS OF
PATIENTS WITH VIRAL HEPATITIS B." Science and innovation 3.D3 (2024): 292-295.
2.
Бурибаева, Бахринисо Исабаевна, and Тожигул Ахмедовна Ниязова. "Изменения в
деятельности сердца при хронических вирусных гепатитах." Молодой ученый 37 (2017): 42-
44.
3.
Арипходжаева, Г. З., А. Х. Хайруллина, and С. А. Рашидова. "Показатели липопероксидации,
антиоксидантной системы и эндогенной интоксикаци при хроническом вирусном гепатите С
во взаимосвязи с уровнем цитолиза." Журнал теоретической и клинической медицины 5
(2015): 120-122.
